GeneCentric Therapeutics, Inc. has entered into a research partnership with G1 Therapeutics Inc. to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP) to identify responders to G1 Therapeutics oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC). As part of the research, GeneCentric will apply its lung cancer subtyping profilers (LSP) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes. This partnership enables GenCentric and G1 Therapeutics to identify subtypes of lung cancer where the compound is most likely to be efficacious.